Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-year Analysis of the MOVER Study

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2014 Nov 8

PMID 25377907

Citations 14

Authors

Hiroshi Hagino

Seitaro Yoshida

Junko Hashimoto

Masayuki Matsunaga

Masato Tobinai

Toshitaka Nakamura

Affiliations

Soon will be listed here.

Abstract

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified into those with or without vertebral fractures. In both the ibandronate group and the risedronate group, hip BMD gains in the patients who had developed no vertebral fractures during the treatment period were greater than in the patients who developed vertebral fractures. We categorized the gains in hip BMD at 6 months into 3 groups (≤0, >0 to ≤3, and >3%), and used logistic regression analysis to estimate odds ratios and the probabilities of incidence of vertebral fractures at 12, 24, and 36 months. The current study demonstrated that greater gains in hip BMD during the first 6 months of treatment were associated with a reduction in the risk of subsequent vertebral fractures during the duration of treatment, and suggested that measurement of hip BMD gain at that time could lead to a prediction of the risk of the future vertebral fracture incidence.

Citing Articles

Effect of subsequent vertebral body fractures on the outcome after posterior stabilization of unstable geriatric fractures of the thoracolumbar spine.

Spiegl U, Jarvers J, Osterhoff G, Kobbe P, Holbing P, Schnake K BMC Musculoskelet Disord. 2022; 23(1):1064.

PMID: 36471332 PMC: 9721076. DOI: 10.1186/s12891-022-06031-z.

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Zheng C, Peterson J, Tugwell P, Liu W Cochrane Database Syst Rev. 2022; 5:CD004523.

PMID: 35502787 PMC: 9062986. DOI: 10.1002/14651858.CD004523.pub4.

Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review.

Imam B, Aziz K, Khan M, Zubair T, Iqbal A Cureus. 2019; 11(8):e5328.

PMID: 31598435 PMC: 6777929. DOI: 10.7759/cureus.5328.

Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.

Hagino H, Sakai A, Ikeda S, Imanishi Y, Tsurukami H, Nakajo S J Bone Miner Metab. 2019; 37(6):1013-1023.

PMID: 31098670 DOI: 10.1007/s00774-019-01005-z.

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study.

Takeuchi Y, Hashimoto J, Kakihata H, Nishida Y, Kumagai M, Yamagiwa C Osteoporos Sarcopenia. 2019; 5(1):11-18.

PMID: 31008373 PMC: 6452926. DOI: 10.1016/j.afos.2019.02.002.

References

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

Sebba A, Emkey R, Kohles J, Sambrook P . Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone. 2008; 44(3):423-7. DOI: 10.1016/j.bone.2008.10.052. View

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

Roux C, Seeman E, Eastell R, Adachi J, Jackson R, Felsenberg D . Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004; 20(4):433-9. DOI: 10.1185/030079903125003125. View

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

Watts N, Cooper C, Lindsay R, Eastell R, Manhart M, Barton I . Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004; 7(3):255-61. DOI: 10.1385/jcd:7:3:255. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

Nancollas G, Tang R, Phipps R, Henneman Z, Gulde S, Wu W . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005; 38(5):617-27. DOI: 10.1016/j.bone.2005.05.003. View

10.

Leslie W, Tsang J, Caetano P, Lix L . Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2006; 92(1):77-81. DOI: 10.1210/jc.2006-1415. View

11.

Harris S, Blumentals W, Miller P . Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2007; 24(1):237-45. DOI: 10.1185/030079908x253717. View

12.

Eisman J, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R . Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008; 35(3):488-97. View

13.

Cranney A, Wells G, Yetisir E, Adami S, Cooper C, Delmas P . Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2008; 20(2):291-7. DOI: 10.1007/s00198-008-0653-8. View

14.

Berger C, Langsetmo L, Joseph L, Hanley D, Davison K, Josse R . Association between change in BMD and fragility fracture in women and men. J Bone Miner Res. 2008; 24(2):361-70. PMC: 5104566. DOI: 10.1359/jbmr.081004. View

15.

Miller P, Delmas P, Huss H, Patel K, Schimmer R, Adami S . Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Calcif Tissue Int. 2010; 87(4):305-13. DOI: 10.1007/s00223-010-9403-y. View

16.

Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M . Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013; 93(2):137-46. PMC: 3717162. DOI: 10.1007/s00223-013-9734-6. View

17.

Zebaze R, Libanati C, Austin M, Ghasem-Zadeh A, Hanley D, Zanchetta J . Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2013; 59:173-9. DOI: 10.1016/j.bone.2013.11.016. View

18.

Miller P, Recker R, Harris S, Silverman S, Felsenberg D, Reginster J . Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int. 2013; 25(1):349-57. DOI: 10.1007/s00198-013-2518-z. View

19.

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View